Taysha Gene Therapies, Inc. (TSHA) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello and welcome to the Tayshia Gene Therapies Second Quarter 2026 Financial Results Conference Call. At this time, all participants are in a listen-only mode. After the speaker presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 11 on your telephone. You will then hear an automated message advising your hand has been raised. To withdraw your question, please press star 11 again. Please be advised that today's conference is being recorded. It is now my pleasure to introduce Vice President of Corporate Communications and Investor Relations, Hayleigh Collins. Thank you. Good afternoon and welcome to Tayshia's 2026 Financial Results and Corporate Update conference call. Earlier today, Tayshia issued a press release announcing financial results for the quarter ended June 30th, 2026. A copy of this press release is available on the company's website and through our FDC file. Joining me on today's call are Sean Nolan, Tayshia's Chief Executive Officer, Sukumar Nagendran, President and Head of R&D, and Kamran Alam, Chief Financial Officer. We will hold a question and answer session following our prepared remarks. On today's call, we will be making forward-looking statements, including statements concerning the potential of Tayshia-102, including the reproducibility and durability of any favorable results initially seen in patients' dose-to-date and clinical trials including with respect to functional milestones to positively impact quality of life and alter the course of disease in the patients we seek to treat. Our research, development, and regulatory plans for our product candidates, including the timing of initiating additional trials, reporting data from our clinical trials, and making regulatory...